Highlights•mAbs mixture targeting independent epitopes are better therapeutics.•Optimizing
antibody efficacy: in vitro maturation, afucosylation, Fc modifications.•Monitoring of natural …

In 1976 Ebola revealed itself to the world, marking the beginning of a series of localized
outbreaks. However, it was the Ebola outbreak that began in 2013 that incited fear and …

Over four years have passed since the beginning of the COVID-19 pandemic. The scientific
response has been rapid and effective, with many therapeutic monoclonal antibodies and …

Ebola disease (EBOD) remains a significant and ongoing threat to African countries,
characterized by a mortality rate of 25% to 90% in patients with high viral load and …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can lead to fatal
outcomes for subgroups of patients with pre-existing co-morbidities. We previously reported …

Ebola disease is a severe disease with extremely high case-fatality rates ranging from 28–
100%. Observations made during the 2013–2016 West African epidemic improved our …

Monoclonal antibodies against the Ebola virus (EBOV) surface glycoprotein are effective
treatments for EBOV disease. Antibodies targeting the EBOV glycoprotein (GP) head epitope …

With the increasing momentum and success of monoclonal antibody therapy in conventional
medical practices, there is a revived emphasis on the development of monoclonal …

Background Ebola virus disease (EVD) survivors experience ocular sequelae including
retinal lesions, cataracts, and vision loss. While monoclonal antibodies targeting the Ebola …

H1N1 influenza virus is a significant global public health concern. Monoclonal antibodies
(mAbs) targeting specific viral proteins such as hemagglutinin (HA) have become an …